PCa Commentary | Volume 158 – October 2021
This Commentary considers the benefits of therapy of the primary tumor in newly diagnosed mHSPC, especially as this patient population grows.
Read MoreSelect Page
Posted by Edward Weber, MD | Oct 2021
This Commentary considers the benefits of therapy of the primary tumor in newly diagnosed mHSPC, especially as this patient population grows.
Read MorePosted by Edward Weber, MD | Sep 2021
This Commentary considers the increased incidence of and evolving treatment options for metastatic hormone-sensitive prostate cancer.
Read MorePosted by Edward Weber, MD | Aug 2021
This Commentary looks at Pylarify, a new PET/CT imaging agent for staging primary prostate cancer and recurrence.
Read MorePosted by Edward Weber, MD | Jul 2021
This Commentary looks at causes and management options for hot flashes, a common side effect of ADT treatment for prostate cancer.
Read MorePosted by Edward Weber, MD | Jun 2021
This Commentary looks at the current state of causes, diagnosis and treatment for neuroendocrine prostate cancer.
Read More